- Home
- RSVR vs COGT Comparison
RSVR vs COGT Comparison
Compare RSVR & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSVR
- COGT
- Stock Information
- Founded
- RSVR 2007
- COGT 2014
- Country
- RSVR United States
- COGT United States
- Employees
- RSVR N/A
- COGT N/A
- Industry
- RSVR Movies/Entertainment
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- RSVR Consumer Discretionary
- COGT Health Care
- Exchange
- RSVR Nasdaq
- COGT Nasdaq
- Market Cap
- RSVR 528.3M
- COGT 555.6M
- IPO Year
- RSVR N/A
- COGT 2018
- Fundamental
- Price
- RSVR $7.80
- COGT $5.44
- Analyst Decision
- RSVR Strong Buy
- COGT Buy
- Analyst Count
- RSVR 1
- COGT 6
- Target Price
- RSVR $12.50
- COGT $15.20
- AVG Volume (30 Days)
- RSVR 80.2K
- COGT 1.2M
- Earning Date
- RSVR 05-28-2025
- COGT 05-06-2025
- Dividend Yield
- RSVR N/A
- COGT N/A
- EPS Growth
- RSVR 1094.24
- COGT N/A
- EPS
- RSVR 0.12
- COGT N/A
- Revenue
- RSVR $158,705,736.00
- COGT N/A
- Revenue This Year
- RSVR $11.41
- COGT N/A
- Revenue Next Year
- RSVR $7.45
- COGT N/A
- P/E Ratio
- RSVR $65.58
- COGT N/A
- Revenue Growth
- RSVR 9.56
- COGT N/A
- 52 Week Low
- RSVR $6.56
- COGT $3.72
- 52 Week High
- RSVR $9.83
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- RSVR 59.56
- COGT 56.27
- Support Level
- RSVR $7.15
- COGT $4.80
- Resistance Level
- RSVR $8.04
- COGT $4.99
- Average True Range (ATR)
- RSVR 0.37
- COGT 0.31
- MACD
- RSVR 0.04
- COGT 0.07
- Stochastic Oscillator
- RSVR 75.26
- COGT 88.56
About RSVR Reservoir Media Inc.
Reservoir Media Inc is an independent music company. The company's segment includes Music Publishing; Recorded Music and others. It generates the maximum of its revenue from the Music Publishing segment.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.